NCT04818281View on ClinicalTrials.gov

Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 27, 2021

Primary Completion Date

December 29, 2021

Study Completion Date

December 29, 2021

Conditions
Covid19
Interventions
BIOLOGICAL

SARS-CoV-2 VLP Vaccine

VLP adjuvanted vaccine

BIOLOGICAL

Placebo

0.9% NaCl

Trial Locations (1)

06200

Dr. Abdurahman Yurtaslan Ankara Oncology Training and Research Hospital Phase I Clinical Study Center, Ankara

Sponsors

Collaborators (1)

Nobel Pharmaceuticals
All Listed Sponsors
collaborator

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

OTHER

collaborator

The Scientific and Technological Research Council of Turkey

OTHER

collaborator

MonitorCRO

INDUSTRY

collaborator

Nobel Pharmaceuticals

INDUSTRY

lead

Ihsan GURSEL, PhD, Prof.

OTHER